What Is PE-22-28?
PE-22-28 peptide is one of the more compelling compounds currently being explored across depression studies, neurogenesis, and broader neural function research circles. It is a synthetic derivative of spadin, a naturally occurring peptide derived from sortilin, and represents a shortened seven-amino-acid analog that researchers have proposed may exhibit superior interactions compared to its parent molecule in laboratory settings.
Spadin is proposed to act as an antagonist to the TREK-1 receptor, a two-pore-domain potassium channel, making it a subject of interest in laboratory research exploring the origins of depressive behavior and neurogenesis regulation. Research by Djillani et al. suggested that shortened analogs of spadin, particularly PE-22-28, may exhibit superior TREK-1 inhibition compared to the original spadin in laboratory models, alongside enhanced stability and potentially more robust neurogenic interactions in these experimental settings. This combination of proposed receptor selectivity, stability, and rapid neurogenic activity has made PE-22-28 a particularly active subject of neuropeptide research in controlled laboratory environments.
PE-22-28 Peptide and Its Proposed Mechanism: TREK-1 Inhibition
To understand what makes this neuropeptide research subject distinctive, it helps to appreciate the TREK-1 channel it is proposed to target in laboratory models. TREK-1 is a two-pore-domain potassium channel thought to play a role in modulating neuronal excitability and neurotransmitter release in laboratory research contexts. Studies in murine models suggested a connection between TREK-1 and depressive behavior in laboratory settings, with the deletion of this receptor appearing to render laboratory models resistant to depressive states.
Research by Djillani et al. proposed that PE-22-28 may bind to and inhibit TREK-1 in laboratory models, potentially modulating potassium ion flow in neural cells and influencing neuronal excitability and neurotransmitter release in these settings. This inhibition is proposed to ultimately lead to an enhanced neurogenic response in laboratory models, possibly promoting the growth of new neurons. Researchers also noted that PE-22-28 appeared to exhibit potentially faster onset of action and a longer half-life relative to naturally occurring spadin in laboratory settings, making it a useful research tool for studying TREK-1 modulation in controlled experimental environments.
PE-22-28 Peptide and Depression Studies
At the core of PE-22-28 neuropeptide research is its proposed interactions with depressive behavior models in laboratory settings. Studies conducted in mouse models of depression suggested the potential of PE-22-28 in moderating depressive-related observations in these laboratory settings, with researchers noting apparent interactions within a relatively short timeframe in these experimental models.
Research by Malberg and Schechter, and by Duman et al., indicated that laboratory models of depression demonstrate a reduced volume of the hippocampus, with conventional research compounds appearing to enhance neurogenesis and potentially increase hippocampal volume in these settings. PE-22-28’s proposed potential to moderate this volume loss through neurogenesis in laboratory models suggested that it may address underlying physiological pathways implicated in depressive behavior in these experimental contexts, making depression studies an active and well-documented area of this peptide’s laboratory research profile.
PE-22-28 Peptide and Neurogenesis Research
One of the most actively discussed areas of PE-22-28 peptide research involves its proposed interactions with neurogenesis and synaptogenesis in laboratory models. Research by Djillani et al. suggested that PE-22-28 may elicit heightened neurogenesis and synaptogenesis in murine laboratory models, with researchers reporting approximately doubled populations of BrdU-positive cells, utilized as a marker for DNA replication, and potentially boosted rates of synapse formation in these settings.
In vitro studies suggested the peptide enhanced both mRNA expression and protein levels of markers of synaptogenesis including PSD-95 and synapsin in laboratory cell models. Researchers also reported a rapid increase in both mRNA expression and protein levels of brain-derived neurotrophic factor (BDNF) in the hippocampus of laboratory models following PE-22-28 exposure, which researchers proposed may confirm the antidepressant-related interactions of this neuropeptide in laboratory settings. Researchers further proposed that PE-22-28 may influence brain cell division in laboratory models through its potential impact on CREB, a transcription factor considered important for neuronal plasticity, memory formation, and spatial memory development in these experimental settings.
PE-22-28 Peptide and Nootropic Research
Building on its neurogenesis research profile, PE-22-28 has also been explored for its potential interactions with learning and memory-related processes in laboratory models. The hippocampus, an area regularly studied in depression research contexts, is also considered to hold a role in learning and memory processes in laboratory settings. Research suggested that by potentially enhancing the regenerative capacity of the hippocampus in laboratory models, PE-22-28 may hold interactions relevant to nootropic research, given the hippocampus’s proposed involvement in learning, memory, and spatial navigation in these experimental settings.
Researchers also noted that while prior animal models suggested removal of the TREK-1 channel might lead to increased seizure susceptibility in laboratory settings, neither spadin nor PE-22-28 appeared to exacerbate seizure activity in these models. Research suggested that PE-22-28 may exhibit protective interactions against seizure activity in laboratory settings, with researchers proposing these findings continue to open new avenues for exploration in the field of TREK-1 modulation research.
PE-22-28 Peptide and Post-Stroke Research
Closely related to its depression studies profile, PE-22-28 has also been explored in laboratory models of post-stroke behavioral changes. Research by Djillani et al. suggested TREK-1 over-expression may be involved in the development of post-stroke behavioral changes in laboratory models, with researchers exploring whether TREK-1 inhibitors such as PE-22-28 may moderate or reverse this upregulation in experimental settings.
Laboratory models exposed to PE-22-28 appeared to exhibit beneficial interactions in these settings, with researchers noting a potentially more rapid onset of action compared to SSRI compounds studied in the same laboratory context. Researchers have been careful to frame all post-stroke laboratory observations as preliminary findings requiring substantial further investigation before any broader conclusions can be drawn.
PE-22-28 Peptide and Muscle Function Research
Rounding out this neuropeptide’s broad laboratory research profile, emerging research has also begun exploring TREK-1’s proposed involvement in facilitating muscle responses to mechanical stimulation in laboratory settings. Research by Lei et al. suggested that inhibiting TREK-1 may enhance muscle contractility in laboratory models, while channel activation appeared to promote muscle relaxation in these settings. Researchers proposed that exploring the contributions of molecules like PE-22-28 to muscle contraction and relaxation may hold promise for understanding aspects of muscle physiology in controlled laboratory environments, though this area of TREK-1 research remains in its early exploratory phase.
References
- Mazella J, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010;8(4):e1000355.
- Djillani A, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017;8:643.
- Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des. 2005;11(2):145–55.
- Duman RS, et al. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology. 2001;25(6):836–44.
- Djillani A, et al. Role of TREK-1 in Health and Disease, Focus on the Central Nervous System. Front Pharmacol. 2019;10:379.
- Lei Q, et al. Response of the human detrusor to stretch is regulated by TREK-1, a two-pore-domain mechano-gated potassium channel. J Physiol. 2014;592(14):3013–30.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
